Clínic Barcelona

Hospital Clínic implements the liquid biopsy to enhance clinical trials in oncology

  • Hospital Clínic will be the first center in Europe to routinely use one of the most advanced liquid biopsy tests available, the Guardant-360, which evaluates alterations in 74 relevant genes in multiple solid tumors.
  • The agreement with the company Guardant Health, Inc. from California will increase the inclusion of patients in clinical trials with more precise drugs.
  • The incorporation of liquid biopsy will improve the current diagnosis and treatment of patients with advanced cancer.
Keep reading about: